Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

Paolo Ghia, MD, PhD, discusses the CAPTIVATE trial in chronic lymphocytic leukemia/small lymphocytic lymphoma, and what findings from the trial have been particularly noteworthy.